Cutler Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Cutler Group’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-170	Closed	-$22K	–	6646
2020 Q4	$22K	Buy	+170	New	+$15K	﹤0.01%	2639
2020 Q3	–	Sell	-1,137	Closed	-$54K	–	5498
2020 Q2	$54K	Buy	+1,137	New	+$52.9K	﹤0.01%	1697
2020 Q1	–	Sell	-6,000	Closed	-$306K	–	4953
2019 Q4	$344K	Buy	+6,000	New	+$297K	0.02%	592

Cutler Group's EIDX Position: Q1 2021 in Review

Cutler Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 170 shares — an estimated $22K sold.

Cutler Group first reported a position in EIDX in Q4 2019 and held it in 3 quarters. The position peaked at $344K in Q4 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Cutler Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Cutler Group sold 170 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $22K.
Cutler Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
Cutler Group's Eidos Therapeutics, Inc. Common Stock position peaked at $344K in Q4 2019.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Cutler Group's 13F filing for Q1 2021, filed 26 Apr 2021.